41.01MMarket Cap-629P/E (TTM)
1.050High0.980Low15.98KVolume1.000Open0.994Pre Close16.06KTurnover0.08%Turnover RatioLossP/E (Static)41.49MShares3.46052wk High0.58P/B18.76MFloat Cap0.95052wk Low--Dividend TTM18.98MShs Float25.780Historical High--Div YieldTTM7.01%Amplitude0.950Historical Low1.004Avg Price1Lot Size
Rallybio Stock Forum
Rallybio Announces Initiation of Phase 2 Clinical Trial of RLYB212
— Screening is Now Underway to Identify Pregnant Women at Higher Risk for HPA-1a Alloimmunization and FNAIT —
Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced the initiation of its Phase 2 clinical trial investigating RLYB212 in pregnant women at higher risk ...
Rallybio Announces Approval of Clinical Trial Applications for Phase 2 Trial of Rlyb212 in Pregnant Women at Higher Risk of Alloimmunization and Fnait
Rallybio to Present Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations at the American Society of Human Genetics 2024 Annual Meeting
Rallybio (Nasdaq: RLYB) will present full data from an epidemiological analysis at the American Society of Human Genetics (ASHG) 2024 Annual Meetingin Denver, CO. The analysis quantifies the proportion of women across diverse populations at higher risk of a fetal and neonatal alloi...
2 MINUTES AGO, 8:00 AM EDT
VIA BUSINESSWIRE
– Study Demonstrates that RLYB212 Rapidly Clears HPA-1a Positive Platelets, an Essential Step in Preventing Alloimmunization and FNAIT –
– Rallybio On Track to Initiate RLYB212 Phase 2 Dose Confirmation Trial in Pregnant Women at Higher Risk for FNAIT in 4Q 2024 –
No comment yet